Figure 6
From: Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma
In vivo antitumor activities of hYP7.
(a) The in vivo inhibition of hepatocellular carcinoma xenograft tumor growth by hYP7 in nude mice. The 20 mg/kg group and the 60 mg/kg group showed significantly slower tumor growth than the control (p < 0.05, tested by paired t test). There were no statistically significant differences (ns) in tumor growth between 20 mg/kg group and 60 mg/kg group when tested with the same method. (b) Body weight measurements. Arrows indicated individual injections; n = 6/group. Values represent mean ± s.e.m.
